VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
BHCBausch Health Companies Inc.
$4.77$1.8B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksBHCP/E History

BHC logoBausch Health Companies Inc. (BHC) P/E Ratio History

Undervalued

Trading at 11.1x vs 5Y avg 93.9x · 20th percentile · Below historical baseline · Data 1995–2025

Current P/E (TTM)
11.1x
-88% vs 5Y avg
5Y Avg P/E
93.9x
Median 55.7x
5Y Percentile
20th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
11.1x
Min2.4xMedian55.7xMax636.8x
TTM EPS$-3.19
Price$4.77
Earnings Yield9.01%
EPS Growth (1Y)430.8%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Bausch Health Companies Inc. (BHC) trades at a price-to-earnings ratio of 11.1x, with a stock price of $4.77 and trailing twelve-month earnings per share of $-3.19.

The current P/E is 88% below its 5-year average of 93.9x. Over the past five years, BHC's P/E has ranged from a low of 2.4x to a high of 636.8x, placing the current valuation at the 20th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, BHC trades at a 50% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, BHC trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BHC DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

BHC Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
11.1vs22.1
-50%
Below Sector
vs. S&P 500
11.1vs24.4
-55%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 431% EPS growth (1Y)

BHC P/E vs Peers

Specialty pharma brand consolidators peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
PBH logoPBHPrestige Consumer Healthcare Inc.
$2B12.03.19-9%
COO logoCOOThe Cooper Companies, Inc.
$13B35.2--5%
ABT logoABTAbbott Laboratories
$154B11.6Lowest0.39Best+134%Best
NVS logoNVSNovartis AG
$281B20.51.33+22%
EW logoEWEdwards Lifesciences Corporation
$50B47.76.74-74%
MCK logoMCKMcKesson Corporation
$90B19.6-+49%
CAH logoCAHCardinal Health, Inc.
$52B34.4-+87%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

BHC Historical P/E Data (1995–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$6.95$0.4017.4x-77%
FY2025 Q3-$6.45$0.966.7x-91%
FY2025 Q2Jun 30 2025$6.66$0.2625.6x-66%
FY2022 Q3Sep 30 2022$6.89$0.739.4x-88%
FY2022 Q2-$8.36$0.1555.7x-26%
FY2017 Q4Dec 31 2017$20.78$8.682.4x-97%
FY2017 Q3Sep 30 2017$14.33$5.392.7x-96%
FY2015 Q3Sep 30 2015$178.38$2.0686.6x+14%
FY2015 Q2-$222.15$2.7780.2x+6%
FY2015 Q1-$198.62$3.3160.0x-21%
FY2014 Q4Dec 31 2014$143.11$3.0347.2x-38%
FY2014 Q3-$131.20$1.6081.9x+8%
FY2012 Q3Sep 30 2012$55.27$0.09636.8x+740%
FY2012 Q2Jun 30 2012$44.79$0.20227.2x+200%
FY2012 Q1Mar 31 2012$53.69$0.43125.4x+66%
FY2011 Q4Dec 31 2011$46.69$0.4995.4x+26%
FY2011 Q3Sep 30 2011$37.12$0.14266.3x+251%
FY2010 Q2Jun 30 2010$19.24$0.9320.7x-73%
FY2010 Q1Mar 31 2010$16.77$0.8819.1x-75%
FY2009 Q4-$13.96$1.2211.4x-85%
FY2009 Q3Sep 30 2009$15.43$1.5210.2x-87%
FY2009 Q2-$13.45$1.588.5x-89%
FY2009 Q1-$10.95$1.258.8x-88%
FY2008 Q4Dec 31 2008$9.45$1.297.3x-90%
FY2008 Q3-$9.77$0.3329.6x-61%
FY2008 Q2Jun 30 2008$9.65$0.4123.5x-69%
FY2008 Q1Mar 31 2008$10.65$1.0210.4x-86%
FY2007 Q4Dec 31 2007$13.46$1.3310.1x-87%
FY2007 Q3Sep 30 2007$17.37$2.257.7x-90%
FY2007 Q2Jun 30 2007$25.42$1.4917.1x-77%
FY2007 Q1Mar 31 2007$21.86$1.6313.4x-82%
FY2006 Q4Dec 31 2006$21.16$1.4614.5x-81%
FY2006 Q3Sep 30 2006$15.24$0.5726.7x-65%
FY2006 Q2Jun 30 2006$23.41$1.6614.1x-81%
FY2006 Q1Mar 31 2006$24.35$1.0922.2x-71%
FY2005 Q4Dec 31 2005$23.73$0.6834.9x-54%
FY2005 Q3Sep 30 2005$23.37$0.4650.9x-33%
FY2005 Q2-$15.52$0.11142.1x+88%
FY2005 Q1-$15.08$0.4533.2x-56%
FY2004 Q4Dec 31 2004$16.53$0.5430.6x-60%
FY2004 Q3-$17.30$0.2959.7x-21%
FY2004 Q2Jun 30 2004$18.98$0.011898.0x+2404%
FY2003 Q2Jun 30 2003$47.06$0.6670.9x-6%
FY2003 Q1Mar 31 2003$39.87$1.2631.6x-58%
FY2002 Q4-$26.41$1.2421.3x-72%
FY2002 Q3Sep 30 2002$24.69$1.7713.9x-82%
FY2002 Q2Jun 30 2002$28.96$1.3421.6x-71%
FY2002 Q1Mar 31 2002$49.98$1.2041.6x-45%
FY2001 Q4Dec 31 2001$56.25$1.0155.7x-27%
FY2001 Q3Sep 30 2001$46.40$0.8654.0x-29%
FY2000 Q2Jun 30 2000$27.72$0.5451.2x-32%
FY2000 Q1Mar 31 2000$22.13$0.4648.0x-37%
FY1999 Q4Dec 31 1999$23.44$0.6337.2x-51%
FY1999 Q3-$12.69$0.6120.8x-73%
FY1999 Q2Jun 30 1999$12.77$0.6419.9x-74%
FY1999 Q1Mar 31 1999$9.63$0.6115.8x-79%
FY1998 Q4-$9.45$0.6015.8x-79%
FY1998 Q3Sep 30 1998$6.73$0.5811.6x-85%
FY1998 Q2-$8.00$0.5215.4x-80%
FY1998 Q1-$12.06$0.4924.8x-67%
FY1997 Q4Dec 31 1997$9.77$0.4621.3x-72%
FY1997 Q3-$7.27$0.3819.0x-75%
FY1997 Q2Jun 30 1997$7.55$0.3422.3x-71%
FY1997 Q1Mar 31 1997$5.81$0.3218.0x-76%
FY1996 Q4-$6.41$0.3021.3x-72%
FY1996 Q3Sep 30 1996$8.88$0.2732.7x-57%
FY1996 Q2Jun 30 1996$7.81$0.1941.2x-46%
FY1996 Q1Mar 31 1996$7.09$0.1258.5x-23%
FY1995 Q4Dec 31 1995$6.44$0.0972.1x-5%

Average P/E for displayed period: 75.8x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

31+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

BHC — Frequently Asked Questions

Quick answers to the most common questions about buying BHC stock.

What is BHC's P/E ratio?

Bausch Health Companies Inc. (BHC) trailing twelve-month P/E ratio is 11.1x, based on TTM diluted EPS of $-3.19. The 5-year average P/E is 93.9x and the historical range spans 2.4x to 636.8x.

Is BHC stock overvalued or undervalued?

BHC trades at 11.1x P/E, below its 5-year average of 93.9x. At the 20th percentile of its historical range (2.4x–636.8x), the stock is priced at a discount to its own history.

Is BHC stock expensive?

No, BHC is not expensive on a historical basis. The current P/E of 11.1x is below the 5-year average of 93.9x and sits at the 20th percentile of its valuation range.

What is BHC's historical P/E range?

Over the past 5 years, BHC's P/E ratio has ranged from 2.4x to 636.8x, with a median of 55.7x and an average of 93.9x. The current P/E of 11.1x places the stock at the 20th percentile of this range. Full historical data spans 1995–2025.

How does BHC's P/E compare to the S&P 500?

BHC trades at 11.1x P/E versus the S&P 500 median of 24.4x. The 55% discount to the market suggests lower growth expectations or perceived higher risk.

How does BHC's valuation compare to Healthcare peers?

Bausch Health Companies Inc. P/E of 11.1x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is BHC's PEG ratio?

BHC PEG ratio is N/A, based on a P/E of 11.1x and EPS growth of 430.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is BHC's earnings yield?

BHC earnings yield is 9.01%, the inverse of its 11.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

BHC P/E Ratio History (1995–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current17.4x
Period Avg93.9x
Range2.4x - 636.8x
Change+52%
20 quartersDec 31, 2009 - Dec 31, 2025